Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1875-1884

  Kortmansky, Jeremy ^a   Shah, Manish A ^a   Kaubisch, Andreas ^a   Weyerbacher, Amanda ^a   Yi, Sandy ^a   Tong, William ^a   Sowers, Rebecca ^a   Gonen, Mithat ^a   O'Reilly, Eileen ^a   Kemeny, Nancy ^a   Ilson, David I ^a   Saltz, Leonard B ^a   Maki, Robert G ^a   Kelsen, David P ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CYCLIN DEPENDENT KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; OROSOMUCOID; PROTEIN KINASE C INHIBITOR; THYMIDYLATE SYNTHASE; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVITY; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOTENSION; HYPOXEMIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; NAUSEA AND VOMITING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; SYNCOPE; TREATMENT RESPONSE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; FEMALE; FLUOROURACIL; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; STAUROSPORINE; TREATMENT OUTCOME;

EID: 20144373035     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.116     Document Type: Article

References (39)

1. Wang Q, Worland PJ, Clark JL, et al: Apoptosis in 7-hydroxystaurosporine- treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927-936, 1995
2. Kawakami K, Futami H, Takahara J, et al: UCIM-01, 7-hydroxyl- staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219:778-783, 1996
3. Akiyama T, Yoshida T, Tsujita T, et al: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57: 1495-1501, 1997
4. Graves PR, Yu L, Schwarz JK, et al: The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605, 2000
5. Sato S, Fujita N, Tsuruo T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727-1738, 2002
6. B. Takahashi I, Saitoh Y, Yoshida M, et al: UCN-01 and UCN-02, new selective inhibitors of protein kinase C: II. Purification, physicochemical properties, structural determination and biological activities. J Antibiot (Tokyo) 42: 571-576, 1989
7. Akinaga S, Gomi K, Morimoto M, et al: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51:4888-4892, 1991
8. Seynaeve CM, Stetler-Stevenson M, Sebers S, et al: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53:2081-2086, 1993
9. Tsuchida E, Urano M: The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma. Int J Radiat Oncol Biol Phys 39:1153-1161, 1997
10. Husain A, Yan XJ, Rosales N, et al: UCN-01 in ovary cancer cells: Effective as a single agent and in combination with cis- diamminedichloroplatinum(II)independent of p53 status. Clin Cancer Res 3:2089-2097, 1997
11. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2:791-797, 1996
12. Akinaga S, Nomura K, Gomi K, et al: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32:183-189, 1993
13. Nieves-Neira W, Pommier Y: Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: Multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 82:396-404, 1999
14. Jones CB, Clements MK, Wasi S, et al: Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G(2) arrest. Cancer Chemother Pharmacol 45:252-258, 2000
15. Tang L, Boise LH, Dent P, et al: Potentiation of 1-beta-D- arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem Pharmacol 60:1445-1456, 2000
16. Abe S, Kubota T, Otani Y, et al: UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. Jpn J Cancer Res 91:1192-1198, 2000
17. Shi Z, Azuma A, Sampath D, et al: S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065-1072, 2001
18. Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849, 2001
19. Hsueh CT, Kelsen D, Schwartz GK: UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 4:2201-2206, 1998
20. Hsueh CT, Wu YC, Schwartz GK: UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. Clin Cancer Res 7:669-674, 2001
21. Sausville EA, Arbuck SG, Messmann R, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333, 2001
22. Fuse E, Tanii H, Kurata N, et al: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248-3253, 1998
23. Tamura T, Sasaki Y, Minami H, et al: Phase I study of UCN-01 by 3-hour infusion. Proc Am Soc Clin Oncol 18:159a, 1999 (abstr 611)
24. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs-Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
25. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998
26. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
27. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053-1058, 1988
28. Haas NB, Hines JB, Hudes GR, et al: Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11:181-185, 1993
29. Weh HJ, Wilke HJ, Dierlamm J, et al: Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma: A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 5:233-237, 1994
30. Bauer KS, Lush RM, Rudek MA, et al: A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 14:338-343, 2000
31. Mancini G, Carbonara AO, Heremans JF: Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2:235-254, 1965
32. Moore MJ, Bunting P, Yuan S, et al: Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 15:394-399, 1993
33. Wakamiya N, Stone N, Takeyama H, et al: Detection of tumor necrosis factor gene expression as a cellular level in human acute myeloid leukemia. Leukemia 3:51-56, 1989
34. Dees C, O'Reilly S, Figg WD, et al: A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor. Proc Am Soc Clin Oncol 19:205a, 2000 (abstr 797)
35. Gandara DR, Lara PN, Longmate J, et al: The cyclin-dependent kinase (CDK) inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium phase I trial. Proc Am Soc Clin Oncol 22:246, 2004 (abstr 987)
36. Hill M, Andjelkovic M, Brazil D, et al: Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 276:25643-25646, 2001
37. Turtle R, Gill N, Pugh W, et al: Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKB-alpha. Nat Med 7:1133-1137, 2001
38. Takamura M, Nio Y, Yamasawa K, et al: Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 13:75-85, 2002
39. Kortmansky J, Sauter N, O'Reilly EM, et al: Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Proc Am Soc Clin Oncol 23: 162a, 2004 (abstr 2140)